Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Phase 2

Dose-Finding Study of HUC1-394 in Participants With Dry Eye Disease

NCT07656688 · tracked via the Priya Life Science South Korea tracker
Phase
Phase 2
Started
2026-07
Last updated
2026-07-01

Condition(s) studied

Dry Eye Disease (DED)

Investigational drug(s) / intervention(s)

HUC1-394Placebo

HUC1-394: ophthalmic solution. Participants will instill 1 drop in each eye

Placebo: ophthalmic solution. Participants will instill 1 drop in each eye

Study summary

Clinical trial aims to determine the optimal dosing regimen by evaluating the efficacy and safety of HUC1-394 across different dosing frequencies in patients with moderate to severe dry eye disease.

Eligibility

Sex
ALL
Min age
19 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Adults aged ≥ 19 years at the time of screening * Trial participants who have experienced at least one of the following dry eye disease symptoms for at least 3 months prior to the time of screening * Trial participants who meet all of the following criteria in at least one eye (left or right) at the time of screening and randomization: TCSS (NEI grading) ≥ 4 / Non-anesthetic Schirmer test result \> 0 mm and ≤ 10 mm/5 min / TBUT \< 7 seconds * OSDI score ≥ 23 at the time of screening * Trial participants who have provided voluntary written informed consent after receiving a full explanation and understanding of the clinical trial Exclusion Criteria: * Trial participants with clinically significant ophthalmic diseases that may confound the interpretation of clinical trial results * Trial participants with blepharospasm, entropion, ectropion, or abnormalities of the eyelashes * Trial participants with any active ophthalmic disease that may affect the ocular surface, such as active allergy, anterior uveitis, and Stevens-Johnson syndrome * Trial participants with a history of corneal transplantation or neurotrophic keratitis * Trial participants with autoimmune diseases or immunodeficiency disorders * Pregnant or lactating women, or women of childbearing potential and men of reproductive potential who plan to conceive during the clinical trial or are unwilling to use an appropriate method of contraception * Trial participants who have participated in another clinical trial and received an investigational product or used an investigational medical device within 30 days prior to the time of screening * Trial participants who are deemed ineligible for participation by the investigator for any other reason in the clinical trial

Primary outcome measure(s)

  • Change from Baseline in Total Corneal Staining Score (TCSS) Using the National Eye Institute (NEI) Scale — Week 12
    NEI scale (range 0-15; higher scores indicate a worse outcome)

Trial sites (1)

FacilityCityRegionStatus
Yonsei University Health System, Severance Hospital Seoul South Korea Recruiting

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07656688 on ClinicalTrials.gov ↗ ← All trials in South Korea